EASL

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Retrieved on: 
Thursday, September 7, 2023
Research, Medical Devices, Clinical Trials, Health Technology, Other Health, Biotechnology, General Health, Health, Science, Other Science, Proton, Fatty liver disease, EASL, NASH, Fibrosis, NDRA, Poster, European Association for the Study of the Liver, Magnetic resonance imaging, Medical imaging, Czechoslovakia, Liver

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.
  • “This poster presentation is focused on a comparison of TAEUS estimates of liver fat fraction to the established clinical gold standard of Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
  • We are delighted that ENDRA's clinical abstract was accepted by EASL for its annual summit focused on steatotic liver disease, which is the target of ENDRA's first TAEUS application.
  • The study data add to ENDRA's growing clinical evidence and illustrate TAEUS' potential to assess fatty liver disease, non-invasively, at the point of care, in populations that include large subjects, and those with NASH or fibrosis,” stated Michael Thornton, Chief Technology Officer of ENDRA.

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, August 21, 2023
Exercise, EASL, IPO, Therapy, NASH, Patient, SAN, Biopsy, Pharmaceutical industry

SAN MATEO, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today reported financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.

Key Points: 
  • SAN MATEO, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today reported financial results for the second quarter ended June 30, 2023, and provided recent corporate updates.
  • Financial Results for the Three Months Ended June 30, 2023
    Cash and cash equivalents for the second quarter ended June 30, 2023 were $18.5 million as of June 30, 2023.
  • Research and development (R&D) expense for the second quarter ended June 30, 2023 was $4.7 million compared to $6.4 million for the second quarter of 2022.
  • Net loss for the second quarter ended June 30, 2023 was $6.8 million compared to a net loss of $7.1 million for the second quarter of 2022.

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Monday, August 14, 2023
Health, Other Science, Clinical Trials, Research, Science, Biotechnology, Proton, Fatty liver disease, EASL, International, Magnetic resonance, De novo, Classification, Marketing, German Diabetes Center, IP, Sale, Trial of the century, Congress, MRI, PIN, Non-alcoholic fatty liver disease, NDRA, Patient, NAFLD, European Association for the Study of the Liver, FDA, Magnetic resonance imaging, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pearson, Food, Medical imaging, Security (finance), Liver

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update.
  • Highlights from the second quarter of 2023 and recent weeks include:
    Submitted a De Novo Request to the U.S. Food and Drug Administration (FDA) for the TAEUS liver system.
  • During the second quarter, ENDRA secured four additional patents, including one in the U.S. and three in China.
  • Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share, compared with a net loss of $3.6 million, or $1.17 per share, in the second quarter of 2022.

CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Leona, EASL, Conference call, PBC, CMC, ULN, ALP, Research, Alkaline phosphatase, European Association for the Study of the Liver, Fibrosis, Primary biliary cholangitis, Hypoglycemia, HIV disease progression rates, Patient, Investment, Risk, Itch, GPR119, UDCA, Therapy, Hand, Technology transfer, Disease, Pharmaceutical industry, Cryptocurrency, Liver, Conference

NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET
    NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023.
  • Research and development expenses for the three months ended June 30, 2023, and 2022 were $19.5 million and $17.9 million, respectively.
  • Research and development expenses for the six months ended June 30, 2023 were $38.1 million and $36.3 million, respectively.
  • Net loss for the six months ended June 30, 2023 was $29.6 million and $54.9 million, or ($0.30) and ($0.62), respectively.

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 10, 2023
Infection, EASL, Interferon gamma, PSA, Prostate cancer, Clinical trial, American depositary receipt, Cancer, Woman, Research, Autoimmunity, AstraZeneca, Hepatitis B, Public expenditure, Arbutus, Retirement, Investigational New Drug, ELISpot, Data, Patient, Laboratory, Immune system, Non-carious cervical lesions, HPV, Depreciation, European Association for the Study of the Liver, Vaccitech, HBV, Oxford University Innovation, IND, Disease, Conference, Safety, OUI, Nivolumab, Vaccine, Pharmaceutical industry, Clothing, Liver, HBsAg

Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.

Key Points: 
  • Data included results for 42 women at Day 35, 7 days after the last dose of VTP-200.
  • The final dataset, including data on clearance of infection and cervical lesions at 12 months post-treatment, is expected in the second quarter of 2024.
  • Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023.
  • Research and development expenses: Research and development expenses were $13.5 million in the second quarter of 2023 compared to $9.8 million in the first quarter of 2023, showing increased spend due to phasing of clinical and pre-clinical trials.

89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023
New England, EASL, Cirrhosis, Histology, Non-cirrhotic portal fibrosis, NASH, F2, Week, Triglyceride, The New England Journal of Medicine, FGF21, Biomarker, ELF, Sale, A1C, Congress, Fibrosis, Vital signs, Patient, Administration, Liver, Fasting, Research and development, DEXA, ALT, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Safety, Glycated hemoglobin, Pharmaceutical industry, Medical imaging, Cryptocurrency, Nature Medicine, G&A, NEJM

SAN FRANCISCO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • The data were simultaneously presented in a late-breaking oral session at the EASL Congress 2023 in Vienna, Austria and were also selected for inclusion in the Best of EASL Congress summary.
  • The Company intends to meet with the U.S. Food and Drug Administration in the second half of 2023 and to pursue European Union scientific advice in parallel.
  • As of June 30, 2023, 89bio had cash, cash equivalents and short-term available-for-sale securities totaling $478.0 million.
  • 89bio reported a net loss of $38.4 million for the three months ended June 30, 2023, compared to a net loss of $25.1 million for the three months ended June 30, 2022.

Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Wednesday, August 9, 2023
GLP, Science, Abstract, EASL, International, Assembly, Biotechnology, HDV, IHW, Viral, SAN, Annual general meeting, Toxicology, Poster, European Association for the Study of the Liver, Research, IND, HBV, Pharmaceutical industry, Vaccine, Cryptocurrency, Liver

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023.
  • “In parallel, our research organization continues to progress towards a second development candidate nomination, which we expect later this year.
  • Assembly Bio’s cash position is projected to fund operations through the third quarter of 2024.
  • General and administrative expenses were $5.0 million for the three months ended June 30, 2023, compared to $6.8 million for the same period in 2022.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
EASL, Medical Affairs Bureau, Hercules, American Diabetes Association, International, Therapy, NASH, Term Asset-Backed Securities Loan Facility, NDA, Type 2 diabetes, Gastroenterology, Evidence, Liver disease, Patient, Risk, Institute for Clinical and Economic Review, ICER, Liver, Fatty liver disease, Commercial, Research, Loan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Cirrhosis, Safety, Pharmaceutical industry, Medical imaging, Rare-earth element, Madrigal

Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration

Key Points: 
  • Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration
    NASH disease education and market development activities expand to support potential first-to-market launch in the U.S.
    CONSHOHOCKEN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports second quarter 2023 financial results.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “The recent submission of the resmetirom NDA represents an important milestone for Madrigal and the NASH community.
  • Madrigal presented the Phase 3 MAESTRO-NASH primary results during the opening general session of the EASL Congress™.
  • Financial Results for the Six Months Ended June 30, 2023
    As of June 30, 2023, Madrigal had cash, cash equivalents and marketable securities of $298.4 million, compared to $358.8 million at December 31, 2022.

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 4, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Serum, HBsAg, Congress, Development, Patient, Risk, Cell, Eli Lilly and Company, CccDNA, Infant, Hepatitis B virus, Hepatitis, Heart, Cash, University, Duchenne muscular dystrophy, Gene, Gene editing, Diaphragm, DSM-IV codes, Precision, Liver cancer, Conditional sentence, European Association for the Study of the Liver, Death, Cirrhosis, IND, Genome, Precision BioSciences, DNA, AAV, Messenger, Hepatocyte, CAR, Administration, Blood, Therapy, HBV, Hemoglobinopathy, EASL, Central nervous system, Molecular Partners, CTA, Inflammation, Skeletal muscle, State Administrative Expenses, DMD, Novartis, OTC, Sickle cell disease, NHP, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Vaccine, Prevail, Liver

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.
  • “The first half of 2023 has been a busy time at Precision.
  • Cash and Cash Equivalents: As of June 30, 2023, Precision had approximately $137.8 million in cash and cash equivalents.
  • Weighted average shares of common stock outstanding were approximately 114.1 million for the quarter ended June 30, 2023, as compared to approximately 68.0 million for the quarter ended June 30, 2022.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.